Amneal Pharmaceuticals, Inc.

Other than as set forth below, there have been no material changes to the disclosures presented in our 2025 Annual Report on Form 10-K under Item 1A. Risk Factors, as supplemented by the disclosure presented in our Quarterly Report on Form 10-Q for the period ended March 31, 2026, filed with the SEC on May 7, 2026.

Risks Related to the Kashiv Acquisition

We may not realize the anticipated benefits of the Kashiv Acquisition, and the acquisition may increase our exposure to existing risks.

We may not realize the anticipated benefits of our acquisition of Kashiv. Additionally, we may experience difficulties integrating Kashiv’s operations, personnel, systems and processes into our business. The acquisition increases our exposure to the risks associated with the development, regulatory approval, manufacturing and commercialization of biosimilar products, including uncertainty regarding the timing and success of product approvals and launches, market acceptance, competition and pricing. In addition, the acquisition increased our indebtedness and may result in significant integration costs, purchase accounting adjustments, impairment charges or other expenses. Any failure to successfully integrate Kashiv, advance its product pipeline or achieve the anticipated financial and strategic benefits of the acquisition could adversely affect our business, financial condition and results of operations.